



#9

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/070,569 |
| | | | | Filing Date | March 8, 2002 |
| | | | | First Named Inventor | Takashi Muramatsu |
| | | | | Art Unit | 1642 |
| | | | | Examiner Name | AM Harris, Ph.D. |
| Sheet | 1 | of | 1 | Attorney Docket Number | SPO-116 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | U1 | US- | | | |
| | U2 | US- | | | |
| | U3 | US- | | | |
| | U4 | US- | | | |
| | U5 | US- | | | |
| | U6 | US- | | | |
| | U19 | US- | | | |
| | U20 | US- | | | |

RECEIVED

FEB 03 2003

TECH CENTER 1600/2900

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| AMH | F1 | JP 6-172218 A <i>abstract on</i> | 6-21-1994 | Mitsui Toatsu Chemicals | --- | |
| | F2 | JP 6-113898 A <i>abstract on</i> | 4-26-1994 | Mitsui Toatsu Chemicals | --- | |
| | F3 | WO 00/31541 A | 6-02-1994 | Georgetown University | --- | |
| | F4 | | | | | |
| | F5 | | | | | |
| | F6 | | | | | |
| | F7 | | | | | |
| | F8 | | | | | |
| | F9 | | | | | |
| | F10 | | | | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| AMH | R1 | Nakagaware <i>et al.</i> "Differential Expression of Pleiotrophin and Midkine in Advanced Neuroblastomas" <i>Cancer Research</i> 55(8):1792-1797, 1995. | |
| AMH | R2 | Ye <i>et al.</i> "Expression of midkine in the early stage of carcinogenesis in human colorectal cancer" <i>British J. Cancer</i> 79(1):179-184, January 1999. | |
| | R3 | | |

| | | | |
|--------------------|-----------|-----------------|-----------|
| Examiner Signature | AM Harris | Date Considered | 7/22/2003 |
|--------------------|-----------|-----------------|-----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



#12

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|--|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/070,569 |
| | | Filing Date | March 8, 2002 |
| | | First Named Inventor | Takashi Muramatsu |
| | | Group Art Unit | 1832 <i>1842</i> |
| | | Examiner Name | <i>AMHarris</i> |
| | | Attorney Docket Number | SPO-116 |

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 1 |
|-------|---|----|---|

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| <i>amh</i> | R1 | ARIDOME, K., J. TSUTSUI, S. TAKAO, K. KADOMATSU, M. OZAWA, T. AIKOU, and T. MURAMATSU. "Increased midkine gene expression in human gastrointestinal cancers." <i>Jpn. J. Cancer Res.</i> July, 1995. 86: 655-661. | |
| | R2 | GARVER, R.I., D.M. RADFORD, H. DONIS-KELLER, M.R. WICK, and P.G. MILNER. "Midkine and pleiotrophin expression in normal and malignant breast tissue." <i>Cancer</i> . September 1, 1994. 74(5): 1584-1590. | |
| | R3 | IKEMATSU, S., A. YANO, K. ARIDOME, M. KIKUCHI, H. KUMAI, H. NAGANO, K. OKAMOTO, M. ODA, S. SAKUMA, T. AIKOU, H. MURAMATSU, K. KADOMATSU, and T. MURAMATSU. "Serum midkine levels are increased in patients with various types of carcinomas." <i>Br. J. Cancer</i> . 2000. 83(6): 701-706. | |
| | R4 | KOIDE, N., H. HADA, T. SHINJI, K. UJIKE, S. HIRASAKI, Y. YUMOTO, T. HANAFUSA, K. KADOMATSU, H. MURAMATSU, T. MURAMATSU, and T. TSUJI. "Expression of the midkine gene in human hepatocellular carcinomas." <i>Hepato-Gastroenterology</i> . 1999. 46: 3189-3196. | |
| | R5 | KONISHI, N., M. NAKAMURA, S. NAKAOKA, Y. HIASA, M. CHO, H. UEMURA, Y. HIRAO, T. MURAMATSU, and K. KADOMATSU. "Immunohistochemical analysis of midkine expression in human prostate carcinoma." <i>Oncology</i> . 1999. 57: 253-257. | |
| | R6 | MURAMATSU, H., <i>et al.</i> "Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas." <i>J. Biochem.</i> 1996. 119: 1171-1175. | |
| | R7 | TSUTSUI, J., K. KADOMATSU, S. MATSUBARA, A. NAKAGAWARA, M. HAMANOUE, S. TAKAO, H. SHIMAZU, Y. OHI, and T. MURAMATSU. "A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas." <i>Cancer Res.</i> 1993. 53: 1281-1285. | |
| | R8 | | |
| | R9 | | |
| | R10 | | |
| | R11 | | |
| | R12 | | |
| | R13 | | |

RECEIVED
DEC 11 2002
TECH CENTER 1600/2000

| | | | |
|--------------------|-----------------|-----------------|------------------|
| Examiner Signature | <i>amharris</i> | Date Considered | <i>7/22/2003</i> |
|--------------------|-----------------|-----------------|------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.